Drug Policy
-
Poilievre’s Leadership Under Review Amid Policy Backlash
Conservative Leader Pierre Poilievre faces a leadership review at the upcoming Calgary convention, amidst significant political blowback over drug policy and accusations of spreading disinformation regarding First Nations consultations on pipelines.
-
DEA Extends Telemedicine Drug Prescribing Amid Venezuela Raid Headlines
The U.S. DEA has extended telemedicine rules for prescribing controlled substances, ensuring patient access through the end of 2026, even as headlines focus on the dramatic U.S. raid and capture of Venezuela’s President Maduro.
-
Trump’s Order Moves Marijuana to Schedule III: What It Means for Patients, Businesses, and Federal Law
President Trump’s executive order reclassifies marijuana as a Schedule III drug, marking a pivotal shift in U.S. drug policy. The move promises tax relief for cannabis businesses, expanded medical research, and potential Medicare coverage for CBD, but leaves recreational use…